PR Newswire10.01.21
Biologica Technologies, developers and marketers of ProteiOS growth factor and OsseoGEN cellular bone matrix, growth factor and OsseoGEN cellular bone matrix, announced clinical data results from a ProteiOS study during the North American Spine Society's (NASS) annual meeting this week in Boston (through Oct. 2). The presentation, "Retrospective assessment of radiographic outcomes after implantation of a novel allograft growth factor combined with scaffold in patients undergoing XLIF, LLIF, and TLIF procedures" was given by Samuel A. Joseph Jr., M.D., of the Joseph Spine Institute of Tampa, Fla., as part of the Innovative Technology Presentation(s) at NASS.
The presentation included numerous data points; a total of 103 levels evaluated for radiographic fusion at time points (three, six, nine, 12, and 18 months), were assessed by a blinded independent radiologist. At three months (n=103) levels were assessed with 37.9 percent demonstrating radiographic fusion (BSF-3), at 12 months (n=83) levels were assessed with 83.1 percent fusion and finally at 18 months (n=80) all levels, 100 percent, demonstrated radiographic fusion (BSF-3).
Before his presentation, Dr. Joseph csaid, "I was initially intrigued by the science and product concept, yet the reliability that ProteiOS has demonstrated in my clinical results shows it is a viable option for a surgeon and their patients."
"It is great to have been working with Dr. Joseph and to have this data that compares very well with published results on autograft and rhBMP-2," Scott Cadotte, senior vice president of Sales and Marketing stated. "We have been hearing similar anecdotal evidence for a while now, but this presentation is a strong first step in validating it."
ProteiOS has been shown to include more than 600 naturally occurring growth factors including but not limited to BMP-2, PDGF, TGF-β1, and VEGF. The product is provided in a lyophilized-format that supports the use of any scaffold approved for use with bone graft, providing flexibility for the surgeon and the hospital.
Founded in 2015, Biologica Technologies is a company focused on providing clinically relevant biologic solutions across multiple medical specialties. Biologica's core proprietary technology is the ability to access intracellular growth factors (GFs) found within allograft tissue. ProteiOS growth factor and OsseoGEN cellular bone matrix are the first products utilizing this technology and possess the highest amount of GFs within their respective biologic categories. The company is privately held and headquartered in Carlsbad, Calif.
The presentation included numerous data points; a total of 103 levels evaluated for radiographic fusion at time points (three, six, nine, 12, and 18 months), were assessed by a blinded independent radiologist. At three months (n=103) levels were assessed with 37.9 percent demonstrating radiographic fusion (BSF-3), at 12 months (n=83) levels were assessed with 83.1 percent fusion and finally at 18 months (n=80) all levels, 100 percent, demonstrated radiographic fusion (BSF-3).
Before his presentation, Dr. Joseph csaid, "I was initially intrigued by the science and product concept, yet the reliability that ProteiOS has demonstrated in my clinical results shows it is a viable option for a surgeon and their patients."
"It is great to have been working with Dr. Joseph and to have this data that compares very well with published results on autograft and rhBMP-2," Scott Cadotte, senior vice president of Sales and Marketing stated. "We have been hearing similar anecdotal evidence for a while now, but this presentation is a strong first step in validating it."
ProteiOS has been shown to include more than 600 naturally occurring growth factors including but not limited to BMP-2, PDGF, TGF-β1, and VEGF. The product is provided in a lyophilized-format that supports the use of any scaffold approved for use with bone graft, providing flexibility for the surgeon and the hospital.
Founded in 2015, Biologica Technologies is a company focused on providing clinically relevant biologic solutions across multiple medical specialties. Biologica's core proprietary technology is the ability to access intracellular growth factors (GFs) found within allograft tissue. ProteiOS growth factor and OsseoGEN cellular bone matrix are the first products utilizing this technology and possess the highest amount of GFs within their respective biologic categories. The company is privately held and headquartered in Carlsbad, Calif.